News Releases | Fact Sheets |
Spokesperson Information
The What's New section provides news releases, updates on programs and services and upcoming events from the Asthma Society of Canada.
.
, lasting from November to April. To know how to prepare for the flu season
For more information please visit www.FightFlu.ca.
of asthma yet to be carried out in the New England Journal of Medicine.
magazine features Dr. Mark Greenwald, Chair of the Asthma Society's Medical and Scientific Advisory Committee.
, is pleased to announce that it has awarded $11 million to fund Canadian research that reduces the morbidity, mortality and socio-economic burden of allergic and related immune diseases. The ASC is proud to partner with AllerGen on some of the funded initiatives.
features ASC Board member Dr. Mark Greenwald in an article about seasonal allergies.
The Importance of Patient-Provider Interactions in Chronic Illness Care.
The new AeroChamber Plus* Flow-Vu* Chamber design was inspired by patients, with simplified instructions on the
product insert, more colorful artwork and enhanced product portability. All of the AeroChamber Plus* Flow-Vu* Chambers
are free from Bisphenol A (BPA) - a chemical that has been potentially linked to negative health effects.
Pulmo Scale displays remaining doses in your metered dose inhaler by weight. For more information or to order go to:
The ASC is pleased to announce that it has joined Imagine Canada's Ethical Fundraising and Financial Accountability Code program. Registered charities which wish to join the program must be vetted and approved by Imagine Canada. For more information on the program, please visit the Imagine Canada website.
may be lacking a sense of urgency and concern about the severity and management of their child's disease, according to the Paediatric Asthma In Canada survey.
New legislation banning smoking in vehicles with children under 16 came into effect in Ontario on January 21, 2009. Please help us make all vehicles carrying children smoke free.
Health Canada has approved Avamys™, a new intranasal medication to treat seasonal allergic rhinitis and its associated symptoms.
The Asthma Society of Canada is pleased to present the online versions of the patient brochure Circle of Care - Taking Control of Asthma.
Asthma Society of Canada on Rogers Daytime TV March 20, 2009. Topic: Asthma and Kids
Ensuring quality of life for adults and children with asthma and allergies in First Nations and Inuit Communities in Canada.
You may have read or heard a lot in the past few days about a study concerning the misdiagnosis of asthma in adults.
In the November 18, 2008 issue of the Canadian Medical Association Journal (CMAJ), there were two articles and one editorial on asthma. Here is the link www.cmaj.ca to that issue, so that you can read for yourself what was written.
The Asthma Society of Canada believes that there are two equally important issues to be discussed: lack of testing and lack of adequate asthma control.
The Asthma Society of Canada unreservedly supports the view in the article that spirometry tests need to be conducted more frequently to diagnose asthma. In fact, the researchers suggest that spirometry could have prevented any misdiagnosis.
Last year the Asthma Society launched the National Asthma Patient Alliance (NAPA) as a way to give a voice to people living with asthma and to advocate for better access to medical care and testing. In May of this year, the NAPA launched the Asthma Patient Bill of Rights. One of the ten rights is access to spirometry and other lung function tests.
In the editorial from the CMAJ that accompanies the articles on asthma, the writers are clear that broader testing is needed. Entitled The Error of Not Measuring Asthma, the editors state:
Failure to make the diagnosis of asthma objectively is unacceptable. A physician who attempted to manage hypertension without measuring blood pressure or to manage hypercholesterolemia without measuring serum cholesterol levels would not be considered to be maintaining an adequate standard of care. Treating asthma without having performed at least spirometry is no different. www.cmaj.ca/cgi/content/full/179/11/1099
It is important that anyone currently taking medications for asthma continue to do so until they can talk to their doctor and arrange for the diagnostic testing.
No less important is that of the estimated 3,000,000 Canadians living with asthma, 60% do not have their symptoms under control.
Striving for optimum control of asthma symptoms is vital for those people living with asthma. In the same way that misdiagnosis has direct and indirect costs for Canadians, so do does lack of control.
For more information on the Asthma Patient Bill of Rights, please go to www.asthma.ca/napa.
As published in Canadian Health Magazine.
Building a national case for better communication: Poor asthma control in Canada gives patients something to talk about.
The new Asthma Society of Canada Bulletin underscores the need for open dialogue between patients and healthcare professionals to better manage the disease.
The Asthma Society of Canada is pleased to inform that the National Asthma Patient Alliance (NAPA) was launched in Hamilton on January 24th and 25th 2007. At this inaugural meeting, a group of asthma patients across Canada collectively discussed emerging issues in asthma management.
Patients also provided their feedback on the first Asthma Patient Bill of Rights. The Asthma Society of Canada initiated the development of the Bill of Rights in 2005 and the process was led by a group of asthma patients drawing on the expertise and resources of asthma experts from across Canada. The purpose of the Bill of Rights is to act as a catalyst and backdrop for the fundamental rights and direction of asthmatic sufferers in Canada.
For the first time, Canadians with asthma will be able to carry one inhaler that provides both maintenance treatment and rapid symptom relief.
Symbicort® SMART™ is a new approach to asthma management that treats the underlying inflammation of the airways, one of the key causes of asthma, with every inhalation - even when used as a rescue medication. Contact your Doctor, Pharmacist or Asthma Educator to find more information about Symbicort® SMART™.
Health Canada has extended the approval of Alvesco®, a novel inhaled corticosteroid for treatment of asthma in adults and adolescents 12 years of age and older. Canadian adolescents living with asthma now have a new treatment option which may help to address compliance with physician-recommended treatments.
Alvesco® was previously approved in September 2006 for the management of asthma in adults 18 years of age and older.
Health Canada has approved Avamys™ (fluticasone furoate nasal spray), a new intranasal medication to treat seasonal allergic rhinitis and its associated symptoms, in patients 12 years of age and older. In patients 12 years of age and older, Avamys™ is proven to relieve overall nasal symptoms of seasonal allergic rhinitis, including nasal congestion, sneezing, itchy and runny nose. As well, Avamys™ is the first prescription intranasal corticosteroid spray to consistently demonstrate significant improvement in relieving overall allergic eye symptoms, including red, itchy and watery eyes.
Asthma Action Study finds Canadians underestimating asthma severity; personal and economic costs high
More >>
Nearly all deaths caused by asthma could be prevented with proper education and management, according to the Asthma Society of Canada.
More >>
Toronto -- June 27, 2003 -- The Asthma Society of Canada yesterday launched its first "Charitable IPO" for its Corporate Builders Series of Sustainability Investment Funds.
More >>
|
